The BCL2 inhibitor venetoclax has complete response rates of up to 50% in chronic
lymphocytic leukemia patients, but secondary resistance reflecting acquired mutations in …

Simple Summary In recent years, next-generation sequencing has become a major tool in
the management of cancer, advancing the diagnosis and treatment of hematological …

Multiple myeloma (MM) is an incurable hematological cancer with high spatial-and temporal-
heterogeneity. Invasive single-point bone marrow sampling cannot capture the tumor …

Aims Multiple myeloma is a genomically complex haematological malignancy with many
genomic alterations recognised as important in diagnosis, prognosis and therapeutic …

Liquid biopsy has been experimented with to identify the mutation of lymphoma based on
next‐generation sequencing (NGS). We applied NGS analysis to circulating tumor DNA …

Angioimmunoblastic T-cell lymphoma (AITL) is a rare disease entity associated with poor
prognosis and no improvement in overall survival over the last 20 years. 1 The genomic …

Liquid biopsy, particularly circulating tumor DNA (ctDNA), has drawn a lot of attention as a
non-or minimal-invasive detection approach for clinical applications in patients with cancer …

Simple Summary Liquid biopsy (LBx) is a novel and promising approach in precision
medicine, suitable for patient management in a wide range of medical conditions. Its utility in …

The amount of HbH has been shown to correlate with the size of the I ATRX i clone.[6] In the
Oxford ATMDS Registry, one patient demonstrated an I ATRX i clone size of 35% and 1.5 …

High-grade B-cell lymphoma, NOS (HGBL-NOS) is a heterogeneous group of aggressive B-
cell lymphomas which share morphologic, immunophenotypic and genetic features with …